SF Wolf, good to tease this out with you. I believe in a healthy discount having to be applied to any management team touting their product, yet, I have to also say Dr. Alkon comes across as being a passionate as well as a credible believer in all of his decades of research work. I hope they have experienced some yet blinded positive anecdotal patient feedback from the trial. I have a very difficult time accepting the possibility of any placebo effect in this patient population. I would further ask whether the problem in discovering any reasonably effective therapies for AD has been caused by the complexity of the disease etiology or is it because BP has taken the easiest road of possible solution for way too long or a combination of both? Is the future of AD therapy more like cancer where hopefully there will be huge breakthroughs some day or will it be solved quite incrementally over an extended period of time with small steps? Or, will it experience the huge completely successful breakthrough of Hep C? I know none of us have the answers here. We have our minds to analyze the company and its managers, with data on the near horizon, and apply our hearts to a limited degree. Good dialogue creates good balance to the situation. I happen to agree with your optimism on this science, just want to keep balanced. Thanks.
News 
Market Data 
Discover 
